Envoy Medical (COCH) Cash & Equivalents (2021 - 2026)

Envoy Medical (COCH) has 6 years of Cash & Equivalents data on file, last reported at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 375.36% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.3 million (up 375.36% YoY), and the FY2025 full-year result was $3.7 million, down 31.81% from the prior year.
• Cash & Equivalents grew to $25.3 million in Q1 2026, from $3.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $25.3 million in Q1 2026 to a low of $68000.0 in Q2 2023.
• A 5-year average of $5.2 million and a median of $4.0 million in 2023 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 5476.21% in 2023, while the deepest fall reached 85.74% in 2023.
• Tracing COCH's Cash & Equivalents over 5 years: stood at $183000.0 in 2022, then jumped by 2205.46% to $4.2 million in 2023, then climbed by 29.96% to $5.5 million in 2024, then slumped by 31.81% to $3.7 million in 2025, then surged by 575.34% to $25.3 million in 2026.
• Business Quant data shows COCH's Cash & Equivalents at $25.3 million in Q1 2026, $3.7 million in Q4 2025, and $3.6 million in Q3 2025.